ACS

Pembrolizumab vs Chemotherapy in microsatellite instability – high or mismatch repair – deficient metastatic colorectal cancer

Yakup Ergün, Medical Oncologist at Bower Hospital, shared a recent article by T. André on X:

“Pembrolizumab Vs chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from KEYNOTE-177 trial.

  • mFU: 73.3 months.
  • Crossover 62%
  • 5y OS55% vs 44%
  • mOS77.5 vs 36.7 months
  • (2y PFS48.3% — CM-8HW72%)
  • Pembrolizumab ? Nivo+İpi?

Title: Pembrolizumab Versus chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study

Authors: T. André, K.-K. Shiu, T.W. Kim, B.V. Jensen, L.H. Jensen, C.J.A. Punt, D. Smith, R. Garcia-Carbonero, J. Alcaide-Garcia, P. Gibbs, C. de la Fouchardiere, F. Rivera, E. Elez,∙ D.T. Le, T. Yoshino, Y. Zuo, D. Fogelman, D. Adelberg and L.A. Diaz

Yakup Ergün

More posts featuring Yakup Ergün.

B.V. Jensen cancer chemotherapy colorectal cancer D. Fogelman K.-K. Shiu L.A. Diaz OncoDaily Oncology pembrolizumab T. André T.W. Kim Yakup Ergün